70 related articles for article (PubMed ID: 15836802)
1. Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan.
Liou YJ; Wang YC; Lin CC; Bai YM; Lai IC; Liao DL; Chen JY
Int J Neuropsychopharmacol; 2005 Sep; 8(3):483-6. PubMed ID: 15836802
[No Abstract] [Full Text] [Related]
2. Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia.
Pae CU
Psychiatry Res; 2008 Dec; 161(3):336-8. PubMed ID: 18977034
[TBL] [Abstract][Full Text] [Related]
3. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia.
Pae CU; Yu HS; Kim JJ; Lee CU; Lee SJ; Jun TY; Lee C; Paik IH
Int J Neuropsychopharmacol; 2004 Dec; 7(4):495-500. PubMed ID: 15151706
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes.
Zai CC; Tiwari AK; Basile V; de Luca V; Müller DJ; Voineskos AN; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Kennedy JL
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):50-6. PubMed ID: 19778569
[TBL] [Abstract][Full Text] [Related]
5. No association between a functional NAD(P)H: quinone oxidoreductase gene polymorphism (Pro187Ser) and tardive dyskinesia.
Hori H; Shinkai T; Matsumoto C; Ohmori O; Nakamura J
Neuromolecular Med; 2006; 8(3):375-80. PubMed ID: 16775388
[TBL] [Abstract][Full Text] [Related]
6. NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristics of human mammary tumors.
Hubackova M; Vaclavikova R; Mrhalova M; Kubackova K; Kodet R; Gut I; Soucek P
Pharmacogenet Genomics; 2009 Jul; 19(7):505-12. PubMed ID: 19494791
[TBL] [Abstract][Full Text] [Related]
7. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis.
Chao C; Zhang ZF; Berthiller J; Boffetta P; Hashibe M
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):979-87. PubMed ID: 16702380
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor.
Tan EC; Chong SA; Mahendran R; Dong F; Tan CH
Biol Psychiatry; 2001 Jul; 50(2):144-7. PubMed ID: 11526996
[TBL] [Abstract][Full Text] [Related]
9. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
[TBL] [Abstract][Full Text] [Related]
10. NAD(P)H: quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia.
Hori H; Ohmori O; Matsumoto C; Shinkai T; Nakamura J
Psychiatry Res; 2003 Jun; 118(3):235-9. PubMed ID: 12834817
[TBL] [Abstract][Full Text] [Related]
11. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.
Chen CH; Wei FC; Koong FJ; Hsiao KJ
Biol Psychiatry; 1997 Apr; 41(7):827-9. PubMed ID: 9084902
[No Abstract] [Full Text] [Related]
12. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.
Patsopoulos NA; Ntzani EE; Zintzaras E; Ioannidis JP
Pharmacogenet Genomics; 2005 Mar; 15(3):151-8. PubMed ID: 15861039
[TBL] [Abstract][Full Text] [Related]
13. NAD(P)H: quinone oxidoreductase polymorphism and lung cancer in Taiwan.
Lin P; Wang HJ; Lee H; Lee HS; Wang SL; Hsueh YM; Tsai KJ; Chen CY
J Toxicol Environ Health A; 1999 Oct; 58(4):187-97. PubMed ID: 10591487
[TBL] [Abstract][Full Text] [Related]
14. Association of bladder cancer risk with an NAD(P)H:quinone oxidoreductase polymorphism in an ethnic Kashmiri population.
Pandith AA; Khan NP; Shah ZA; Shah AM; Wani SM; Siddiqi MA
Biochem Genet; 2011 Aug; 49(7-8):417-26. PubMed ID: 21253823
[TBL] [Abstract][Full Text] [Related]
15. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.
Kang SG; Choi JE; An H; Lim SW; Lee HJ; Han C; Kim YK; Kim SH; Cho SN; Lee MS; Joe SH; Jung IK; Kim L
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1545-8. PubMed ID: 18602732
[TBL] [Abstract][Full Text] [Related]
16. [The NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and susceptibility to esophageal cancer].
Zhang JH; Li Y; Wang R; Sarbia M; Guo W; Wen DG; Wei LZ; Chen ZF; Kuang G; Zhang LW; He M; Wu ML; Wang SJ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Dec; 20(6):544-6. PubMed ID: 14669229
[TBL] [Abstract][Full Text] [Related]
17. No association between Helicobacter pylori seropositivity and ornithine decarboxylase (ODC) A317G polymorphism, and no modification by NAD(P)H:qinone oxidoreductase 1 (NQO1) C609T.
Goto Y; Nishio K; Ishida Y; Kawai S; Osafune T; Naito M; Katsuda N; Hamajima N
Nagoya J Med Sci; 2007 Jan; 69(1-2):17-22. PubMed ID: 17378176
[TBL] [Abstract][Full Text] [Related]
18. [Association between NAD(P)H: quinone oxidoreductase and apolipoprotein E gene polymorphisms in Alzheimer's disease].
Ma QL; Yang JF; Shao M; Dong XM; Chen B
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(24):2124-7. PubMed ID: 14720419
[TBL] [Abstract][Full Text] [Related]
19. Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia.
Shinkai T; De Luca V; Hwang R; Matsumoto C; Hori H; Ohmori O; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Nakamura J; Kennedy JL
Neurosci Lett; 2005 Nov; 388(2):116-20. PubMed ID: 16039055
[TBL] [Abstract][Full Text] [Related]
20. Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract.
Sarbia M; Bitzer M; Siegel D; Ross D; Schulz WA; Zotz RB; Kiel S; Geddert H; Kandemir Y; Walter A; Willers R; Gabbert HE
Int J Cancer; 2003 Nov; 107(3):381-6. PubMed ID: 14506737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
